Nixon Peabody Trust Co. Has $11.25 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Nixon Peabody Trust Co. raised its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 11.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 63,823 shares of the medical research company's stock after purchasing an additional 6,684 shares during the quarter. Nixon Peabody Trust Co.'s holdings in IQVIA were worth $11,252,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. American National Bank & Trust bought a new position in shares of IQVIA in the first quarter valued at about $26,000. ST Germain D J Co. Inc. raised its holdings in IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares during the period. GKV Capital Management Co. Inc. acquired a new stake in IQVIA during the fourth quarter worth approximately $39,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA during the fourth quarter worth approximately $44,000. Finally, Zions Bancorporation N.A. grew its position in shares of IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on IQV shares. Citigroup restated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Wall Street Zen downgraded shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Truist Financial cut their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a report on Thursday, April 10th. Hsbc Global Res cut shares of IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Finally, Stifel Nicolaus cut their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $226.32.

IQVIA Price Performance

IQV stock traded down $0.68 during midday trading on Thursday, reaching $147.22. 3,264,210 shares of the stock were exchanged, compared to its average volume of 1,590,596. The company has a fifty day moving average price of $148.65 and a 200 day moving average price of $179.70. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The stock has a market capitalization of $25.47 billion, a PE ratio of 19.63, a P/E/G ratio of 1.99 and a beta of 1.28. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.54 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.